Format
Sort by
Items per page

Send to

Choose Destination

Best matches for antidiabetics AND cardiovascular diseases AND cardiovascular event AND sulfonylurea compounds:

Search results

Items: 1 to 20 of 32

1.

Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.

Thrasher J.

Am J Cardiol. 2017 Jul 1;120(1S):S4-S16. doi: 10.1016/j.amjcard.2017.05.009. Epub 2017 May 30. Review.

2.

Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.

Paneni F, Lüscher TF.

Am J Cardiol. 2017 Jul 1;120(1S):S17-S27. doi: 10.1016/j.amjcard.2017.05.015. Epub 2017 May 30. Review.

3.

Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.

Paneni F, Lüscher TF.

Am J Med. 2017 Jun;130(6S):S18-S29. doi: 10.1016/j.amjmed.2017.04.008. Review.

4.

Cardiac Effects of Sulfonylurea-Related Hypoglycemia.

Middleton TL, Wong J, Molyneaux L, Brooks BA, Yue DK, Twigg SM, Wu T.

Diabetes Care. 2017 May;40(5):663-670. doi: 10.2337/dc16-1972. Epub 2017 Feb 21.

PMID:
28223296
5.
6.

Mortality and Cardiovascular Risk of Sulfonylureas in South Asian, Chinese and Other Canadians with Diabetes.

Ke C, Morgan S, Smolina K, Gasevic D, Qian H, Khan N.

Can J Diabetes. 2017 Apr;41(2):150-155. doi: 10.1016/j.jcjd.2016.08.218. Epub 2016 Oct 21.

PMID:
27776891
7.

Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.

van der Leeuw J, Visseren FL, Woodward M, van der Graaf Y, Grobbee DE, Harrap S, Heller S, Mancia G, Marre M, Poulter N, Zoungas S, Chalmers J.

Diabetologia. 2016 Dec;59(12):2603-2612. Epub 2016 Sep 1.

PMID:
27586250
8.

Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score.

Woodward M, Hirakawa Y, Kengne AP, Matthews DR, Zoungas S, Patel A, Poulter N, Grobbee R, Cooper M, Jardine M, Chalmers J; ADVANCE Collaborative Group.

Diabetes Obes Metab. 2016 Mar;18(3):289-94. doi: 10.1111/dom.12614. Epub 2016 Jan 15.

PMID:
26661693
9.

Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer.

Abdelmoneim AS, Eurich DT, Light PE, Senior PA, Seubert JM, Makowsky MJ, Simpson SH.

Diabetes Obes Metab. 2015 Jun;17(6):523-32. doi: 10.1111/dom.12456. Epub 2015 Mar 20. Review.

PMID:
25711240
10.

Mortality risk among sulfonylureas: a systematic review and network meta-analysis.

Simpson SH, Lee J, Choi S, Vandermeer B, Abdelmoneim AS, Featherstone TR.

Lancet Diabetes Endocrinol. 2015 Jan;3(1):43-51. doi: 10.1016/S2213-8587(14)70213-X. Epub 2014 Oct 22.

PMID:
25466239
11.

Refitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.

McEwan P, Bennett H, Ward T, Bergenheim K.

Pharmacoeconomics. 2015 Feb;33(2):149-61. doi: 10.1007/s40273-014-0225-z.

PMID:
25344660
12.

Combination therapy with metformin plus sulphonylureas versus metformin plus DPP-4 inhibitors: association with major adverse cardiovascular events and all-cause mortality.

Morgan CL, Mukherjee J, Jenkins-Jones S, Holden SE, Currie CJ.

Diabetes Obes Metab. 2014 Oct;16(10):977-83. doi: 10.1111/dom.12306. Epub 2014 May 22.

PMID:
24762119
13.

The relationship between alcohol consumption and vascular complications and mortality in individuals with type 2 diabetes.

Blomster JI, Zoungas S, Chalmers J, Li Q, Chow CK, Woodward M, Mancia G, Poulter N, Williams B, Harrap S, Neal B, Patel A, Hillis GS.

Diabetes Care. 2014;37(5):1353-9. doi: 10.2337/dc13-2727. Epub 2014 Feb 27. Erratum in: Diabetes Care. 2015 Jul;38(7):1393.

PMID:
24578358
14.

Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.

Landman GW, de Bock GH, van Hateren KJ, van Dijk PR, Groenier KH, Gans RO, Houweling ST, Bilo HJ, Kleefstra N.

PLoS One. 2014 Feb 12;9(2):e82880. doi: 10.1371/journal.pone.0082880. eCollection 2014. Review.

15.

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

Green JB, Bethel MA, Paul SK, Ring A, Kaufman KD, Shapiro DR, Califf RM, Holman RR.

Am Heart J. 2013 Dec;166(6):983-989.e7. doi: 10.1016/j.ahj.2013.09.003. Epub 2013 Oct 23.

PMID:
24268212
16.

Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.

Ghotbi AA, Køber L, Finer N, James WP, Sharma AM, Caterson I, Coutinho W, Van Gaal LF, Torp-Pedersen C, Andersson C.

Diabetes Care. 2013 Nov;36(11):3746-53. doi: 10.2337/dc13-0027. Epub 2013 Oct 2.

17.
18.

Fibroblast KATP currents modulate myocyte electrophysiology in infarcted hearts.

Benamer N, Vasquez C, Mahoney VM, Steinhardt MJ, Coetzee WA, Morley GE.

Am J Physiol Heart Circ Physiol. 2013 May;304(9):H1231-9. doi: 10.1152/ajpheart.00878.2012. Epub 2013 Feb 22.

19.

Evolution of exenatide as a diabetes therapeutic.

Bhavsar S, Mudaliar S, Cherrington A.

Curr Diabetes Rev. 2013 Mar 1;9(2):161-93. Review.

20.

Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.

Bergenstal RM, Li Y, Porter TK, Weaver C, Han J.

Diabetes Obes Metab. 2013 Mar;15(3):264-71. doi: 10.1111/dom.12026. Epub 2012 Nov 12.

Supplemental Content

Loading ...
Support Center